Yes!! BE is getting lots of attention. Brensocatib is considered to have a safe profile. On a recent call with industry and clinicians there was consensus that their drug would probably not need to be reviewed by the FDA adverse event committee.

Also, it’s meant for people who have frequent exacerbations.

Arina-1 Will perhaps be appropriate for the general bronchiectasis population.